Kidney Failure Clinical Trial
— DESIREOfficial title:
Feasibility Testing a shareD dEciSIon Making Intervention for People With Kidney failuRE (DESIRE), Their Relatives, and the Health Professionals in Kidney Services: a Pilot Randomized Controlled Trial Study Protocol
Verified date | February 2023 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this research is to test the acceptability and feasibility of a shared decision making intervention and a patient decision aid to support patients with kidney failure, relatives, and health professionals in planning and deciding about end-of-life care together.
Status | Completed |
Enrollment | 27 |
Est. completion date | October 6, 2023 |
Est. primary completion date | October 6, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 75 Years and older |
Eligibility | Inclusion Criteria: - Adults with kidney failure on haemodialysis, peritoneal dialysis, or on conservative kidney management and their relatives will be considered for participation. Inclusion criteria will be adults =75 years of age, with an estimated glomerular filtration rate <15, and not suited for a kidney transplant. Exclusion Criteria: - Adults who are cognitively unable to participate will be excluded from the research. |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change in the patient's palliative care needs | The primary outcome will be the change in the adults' palliative needs, as measured using the Integrated Palliative Outcome Score (IPOS)-Renal patient version questionnaire | Through study completion, an average of 6 months | |
Secondary | Participants and relatives' experiences of shared decision making and health professionals' conduction of shared decision making are secondary outcomes. | Participants and relatives' experiences of shared decision making, as measured using the Patient Experience of Shared Decision Making (SHARED) tool and healthprofessionals' conduction of shared decision making, as measured using the Decision Support Analysis Tool (DSAT-10) are secondary outcomes. | Through study completion, an average of 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02546037 -
Clotting With Different Dialyzer Membranes
|
||
Recruiting |
NCT02545920 -
To Assess Ear Blood Flow During Dialysis
|
||
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A | |
Completed |
NCT00986947 -
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
|
Phase 2 | |
Completed |
NCT01158742 -
Live Kidney Donor Study -Renal Function Study
|
N/A | |
Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
Withdrawn |
NCT00807274 -
Renal Function in Adults With Congenital Heart Disease.
|
N/A | |
Completed |
NCT00369382 -
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
|
Phase 4 | |
Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05324878 -
Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
|
||
Completed |
NCT05272800 -
BIS-guided Fluid Management in HD Patients
|
N/A | |
Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Completed |
NCT03723668 -
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
|
||
Recruiting |
NCT04277377 -
Nanoparticle for DSA Removal
|
||
Terminated |
NCT00450333 -
Dynepo Infrequent Dosing Study
|
Phase 3 | |
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT04714853 -
Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins
|